Effect of Roux-en-Y bariatric surgery on lipoproteins, insulin resistance, and systemic and vascular inflammation in obesity and diabetes

Frontiers in Immunology

Volumn 8, Issue NOV, 2017, Pages

  Yadav, Rahul ^a   Hama, Salam ^a   Liu, Yifen ^a   Siahmansur, Tarza ^a   Schofield, Jonathan ^a,b   Syed, Akheel A ^c,d   France, Michael ^b   Pemberton, Philip ^b   Adam, Safwaan ^a   Ho, Jan Hoong ^a   Aghamohammadzadeh, Reza ^a   Dhage, Shaishav ^a   Donn, Rachelle ^d   Malik, Rayaz A ^a,e   New, John P ^c,d   Jeziorska, Maria ^d   Durrington, Paul ^a   Ammori, Basil A ^c   Soran, Handrean ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e WEILL CORNELL MEDICAL COLLEGE   (Qatar)

Author keywords

Diabetes; Insulin resistance; Lipoproteins; Roux en Y; Vascular inflammation

Indexed keywords

ADIPONECTIN; ATORVASTATIN; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LEPTIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN RESISTANCE; OBESITY; ROUX-EN-Y GASTRIC BYPASS; WAIST CIRCUMFERENCE;

EID: 85034026945     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.01512     Document Type: Article

References (35)

1. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet (2011) 377:557-67. doi:10.1016/S0140-6736(10)62037-5
2. Finkelstein EA, Khavjou OA, Thompson H, Trogdon JG, Pan L, Sherry B, et al. Obesity and severe obesity forecasts through 2030. Am J Prev Med (2012) 42:563-70. doi:10.1016/j.amepre.2011.10.026
3. Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet (2009) 373:1083-96. doi:10.1016/S0140-6736(09)60318-4
4. Sjostrom L. Review of the key results from the Swedish obese subjects (SOS) trial-a prospective controlled intervention study of bariatric surgery. J Intern Med (2013) 273:219-34. doi:10.1111/joim.12012
5. Smitka K, Maresova D. Adipose tissue as an endocrine organ: an update on pro-inflammatory and anti-inflammatory microenvironment. Prague Med Rep (2015) 116:87-111. doi:10.14712/23362936.2015.49
6. Ridker PM. C-reactive protein, inflammation, and cardiovascular disease: clinical update. Tex Heart Inst J (2005) 32:384-6
7. Dahlman I, Kaaman M, Olsson T, Tan GD, Bickerton AS, Wåhlén K, et al. A unique role of monocyte chemoattractant protein 1 among chemokines in adipose tissue of obese subjects. J Clin Endocrinol Metab (2005) 90:5834-40. doi:10.1210/jc.2005-0369
8. Perkins JM, Joy NG, Tate DB, Davis SN. Acute effects of hyperinsulinemia and hyperglycemia on vascular inflammatory biomarkers and endothelial function in overweight and obese humans. Am J Physiol Endocrinol Metab (2015) 309:E168-76. doi:10.1152/ajpendo.00064.2015
9. Ingelsson E, Hulthe J, Lind L. Inflammatory markers in relation to insulin resistance and the metabolic syndrome. Eur J Clin Invest (2008) 38:502-9. doi:10.1111/j.1365-2362.2008.01962.x
10. Nedvidkova J, Smitka K, Kopsky V, Hainer V. Adiponectin, an adipocyte-derived protein. Physiol Res (2005) 54:133-40
11. Fain JN. Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. Mediators Inflamm (2010) 2010:513948. doi:10.1155/2010/513948
12. Netto BD, Bettini SC, Clemente AP, Ferreira JP, Boritza K, Souza Sde F, et al. Roux-en-Y gastric bypass decreases pro-inflammatory and thrombotic biomarkers in individuals with extreme obesity. Obes Surg (2015) 25:1010-8. doi:10.1007/s11695-014-1484-7
13. Viana EC, Araujo-Dasilio KL, Miguel GP, Bressan J, Lemos EM. Gastric bypass and sleeve gastrectomy: the same impact on IL-6 and TNF-alpha. Prospective clinical trial. Obes Surg (2013) 23:1252-61. doi:10.1007/s11695-013-0894-2
14. Pontiroli AE, Frige F, Paganelli M, Folli F. In morbid obesity, metabolic abnormalities and adhesion molecules correlate with visceral fat, not with subcutaneous fat: effect of weight loss through surgery. Obes Surg (2009) 19:745-50. doi:10.1007/s11695-008-9626-4
15. Pontiroli AE, Pizzocri P, Koprivec D, Vedani P, Marchi M, Arcelloni C, et al. Body weight and glucose metabolism have a different effect on circulating levels of ICAM-1, E-selectin, and endothelin-1 in humans. Eur J Endocrinol (2004) 150:195-200. doi:10.1530/eje.0.1500195
16. Hanusch-Enserer U, Zorn G, Wojta J, Kopp CW, Prager R, Koenig W, et al. Non-conventional markers of atherosclerosis before and after gastric banding surgery. Eur Heart J (2009) 30:1516-24. doi:10.1093/eurheartj/ehp108
17. Konukoglu D, Uzun H, Firtina S, Cigdem Arica P, Kocael A, Taskin M. Plasma adhesion and inflammation markers: asymmetrical dimethyl-L-arginine and secretory phospholipase A2 concentrations before and after laparoscopic gastric banding in morbidly obese patients. Obes Surg (2007) 17:672-8. doi:10.1007/s11695-007-9113-3
18. Silva-Nunes J, Oliveira A, Duarte L, Barradas M, Melao A, Brito M, et al. Factors related with adiponectinemia in obese and normal-weight women and with its variation in weight loss programs. Obes Facts (2013) 6:124-33. doi:10.1159/000350664
19. Charlton-Menys V, Chobotova J, Durrington PN. Use of the TLX ultracentrifuge for the isolation of different density lipoproteins and effects of freeze/thawing of human plasma before ultracentrifugation. Clin Chem Lab Med (2008) 46:1285-8. doi:10.1515/CCLM.2008.254
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia (1985) 28:412-9. doi:10.1007/BF00280883
21. Rao SR. Inflammatory markers and bariatric surgery: a meta-analysis. Inflamm Res (2012) 61:789-807. doi:10.1007/s00011-012-0473-3
22. Bachmayer C, Lammert A, Hasenberg T, Hammes HP. Healthy obese and post bariatric patients-metabolic and vascular patterns. Exp Clin Endocrinol Diabetes (2013) 121:483-7. doi:10.1055/s-0033-1347248
23. Auguet T, Terra X, Hernandez M, Sabench F, Porras JA. Clinical and adipocytokine changes after bariatric surgery in morbidly obese women. Obesity (Silver Spring) (2014) 22:188-94. doi:10.1002/oby.20470
24. Sdralis E, Argentou M, Mead N, Kehagias I, Alexandridis T, Kalfarentzos F. A prospective randomized study comparing patients with morbid obesity submitted to sleeve gastrectomy with or without omentectomy. Obes Surg (2013) 23:965-71. doi:10.1007/s11695-013-0925-z
25. Holst JJ, Madsbad S. Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor. Surg Obes Relat Dis (2016) 12:1236-42. doi:10.1016/j.soard.2016.02.033
26. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab (2003) 88:4848-56. doi:10.1210/jc.2003-030519
27. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature (2001) 409:307-12. doi:10.1038/35053000
28. Marantos G, Daskalakis M, Karkavitsas N, Matalliotakis I, Papadakis JA, Melissas J. Changes in metabolic profile and adipoinsular axis in morbidly obese premenopausal females treated with restrictive bariatric surgery. World J Surg (2011) 35:2022-30. doi:10.1007/s00268-011-1165-9
29. Choy JC, Granville DJ, Hunt DW, McManus BM. Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol (2001) 33:1673-90. doi:10.1006/jmcc.2001.1419
30. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation (2003) 108:736-40. doi:10.1161/01.CIR.0000084503.91330.49
31. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun (2004) 314:415-9. doi:10.1016/j.bbrc.2003.12.104
32. Durrington PN. Hyperlipidaemia Diagnosis and Management. 3rd ed. London: Hodder Arnold (2007)
33. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med (1993) 94:350-6. doi:10.1016/0002-9343(93)90144-E
34. Younis NN, Soran H, Sharma R, Charlton-Menys V, Greenstein A, Elseweidy MM, et al. Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes. Diab Vasc Dis Res (2010) 7:289-95. doi:10.1177/1479164110383063
35. Zambon S, Romanato G, Sartore G, Marin R, Busetto L, Zanoni S, et al. Bariatric surgery improves atherogenic LDL profile by triglyceride reduction. Obes Surg (2009) 19:190-5. doi:10.1007/s11695-008-9644-2